Study With a Topical Gel to Treat Common Warts in Adults
Phase 2
Completed
- Conditions
- Warts
- Registration Number
- NCT00117871
- Lead Sponsor
- Graceway Pharmaceuticals, LLC
- Brief Summary
The primary purpose of this study is to evaluate the effectiveness in adults of 2 different strengths of resiquimod gel applied to common wart(s) five times a week for up to 12 weeks.
A second purpose is to evaluate the safety of the drug.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
- Diagnosis of common warts
- Two forms of birth control
Exclusion Criteria
- Pregnant or breast feeding
- Other types of warts, ie. plantar
- Currently participating in another clinical study
- Chronic viral hepatitis B or C
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Clearance of treated wart(s)
- Secondary Outcome Measures
Name Time Method Partial clearance of treated wart(s)
Trial Locations
- Locations (1)
Minnesota Clinical Study Center
🇺🇸Fridley, Minnesota, United States